slideshowslideshowslideshowslideshow

plavix generic equivalent

Pharmacological action:

Active ingredient Plavix-clopidogrel. Clopidogrel-antitrombocitarnoe tool, which selectively suppresses the binding of ADP (ADP) with surface receptors on platelets. Thanks to this occurs due to activation of ADP-complex GP IIb/IIIA, which leads to inhibition of platelet aggregation. Just as the drug causes and other reactions that contribute to suppression of platelet aggregation. Effect of the drug on platelets is irreversible, so these platelets over a lifetime will be unable to form aggregates. Restoration there properties of platelets occurs in the formation of new cells.

After internal application klopidogrela in a dose of 75 mg per day rapid absorption, but the content of the original substance in plasma is small-only after 2:00 there is concentration of available limit of measurement-0.00025 mg/l Absorption of the drug within 50%, which can be traced back to a level of eliminiruusihsa metabolites in the urine. The main metabolite is derived-has has no pharmacological effect and makes up 85% of the original substance that circulates in the blood. Klopidogrela metabolism takes place in the liver. Cmax (approximately 3 mL/kg) carboxylic derivative in plasma is a 60 minute provided re-employment Plavix at a dose of 75 mg.

plavix inhibition test

Clopidogrel is a prodrug. The active metabolite-tiolovoe derivative is metabolized through oxidation of klopidogrela in 2-oksoklopidogrel. Subsequently, 2-oksiklopidogrel hydrolyzed. Klopidogrela oxidation phase is regulated mainly cytochrome izofermentami (ZA4 and P450 2v6) and slightly-enzymes 1A2, 1A1 and 2s19. Tiolovoe derivative, selected in vitro, quickly and irreversibly binds to the receptors platelets, which leads to irreversible inhibition of aggregation. Kinetic study of the main metabolite showed a linear relationship between dose of 50 to 150 mg klopidogrela (increase of plasma metabolite depending on dosage).

plavix trade name

In vitro found reversible binding of the main circulating metabolite and klopidogrela human blood plasma proteins (respectively 94 and 98%).
Half-life tiol?nogo metabolita-8:00 as in the case of a single or repeated application. Off: 50% in the urine, bowel problems-46%.

Indications for use:

For the prevention of aterotromboza in patients with:
· ischemic stroke-appointed between 7 days up to 6 months after ischemic stroke;
· confirmed peripheral arterial disease;
· myocardial infarction-drug designation is justified after a few days (up to a maximum of 35 days after myocardial infarction);
· acute coronary syndrome without S-T segment elevation in combination with acetylsalicylic acid (myocardial infarction in the absence of pathological zubza Q on the electrocardiogram, unstable angina).

Method of application:

Plavix is taken inside. Adult dose is 75 mg/day, regardless of the meal. In patients younger than 18 years, the safety and efficacy of the drug is not installed.

Acute coronary syndrome without S-T segment elevation-starting dose is 300 mg once, and then appoint supportive treatment in a dose of 75 mg/day in combination with acetylsalicylic acid from 75 to 325 mg per day. The optimal duration of therapy has not been established. The maximum effect is registered through 3 months of admission Plavix generic equivalent. Sometimes shows therapy for up to 1 year.

Prevention of ischemia in patients after ischemic stroke, myocardial infarction and peripheral artery syndrome okkluzionnom confirmed-to 75 mg/day since the early days of the disease up to 35 days (myocardial infarction) and 7 days to 6 months-after suffering an ischemic stroke.

Side effects:

Gastrointestinal: abdominal pain, diarrhoea disorders ; nausea, flatulence, gastritis, constipation, vomiting, peptic ulcer of the duodenum and stomach ; pancreatitis, increasing transaminaz, hepatitis, colitis, including ulcerative or Lymphocytic.

Central nervous system: dizziness, headache, paresthesia (undistributed); sputannosti consciousness, taste hallucinations (very rare).